Bigfoot Biomedical touts cloud-based program for managing diabetes

Bigfoot Biomedical officials think their Bigfoot Unity diabetes management program and Bigfoot Clinic Hub could up […]

Bigfoot Biomedical officials think their Bigfoot Unity diabetes management program and Bigfoot Clinic Hub could up the game in the space.

Milpitas, California-based Bigfoot designed the Bigfoot Unity platform to allow healthcare professionals (HCPs) to review patient data. The information comes from the patient’s prescribed Bigfoot Unity system, integrating with Abbott’s FreeStyle Libre 2 continuous glucose monitor (CGM). Data, including CGM and insulin dose timing information, is automatically captured by smart insulin pen caps and a mobile app and uploaded to the Bigfoot Clinic Hub secure web portal whenever WiFi or a cellular signal is present.

In June, Bigfoot launched Bigfoot Unity in California, Texas, Florida, Pennsylvania, Ohio, New York, New Jersey, Massachusetts and other New England states. The company offers the program as a bundle of devices, supplies and services and delivered as a 30-day subscription to eliminate upfront costs.

Bigfoot Unity generally should be covered by insurance, according to the company. However, copays could vary. The availability of the Bigfoot Unity program, which received FDA clearance in May, will expand to other markets throughout 2021 and 2022.

Clinic Hub features a streamlined patient report format designed to offer meaningful, at-a-glance data. It allows the HCP to quickly review the practice’s entire Bigfoot Unity patient population and filter for those who are experiencing more frequent high or low glucose levels, according to a news release.

The HCP can then select the individual patient report with an integrated graph tracking both CGM and time of insulin dose data. The report also offers time-in-range and other parameters in a standardized format.

Additionally, Bigfoot Clinic Hub supports the clinics in providing remote physiologic monitoring (RPM) services, with billing guidance documenting relevant data.

“The traditional treatment plan for people with Type 1 or Type 2 diabetes on MDI therapy is simply not working for health care professionals or their patients,” Bigfoot Biomedical CMO Dr. Jim Malone said in the release. “We’ve created a first-of-its-kind, HCP-centered solution that supports clinicians to efficiently deliver proactive care with a much-needed level of simplicity and convenience to facilitate both patient adherence and practice implementation.”

Original Article: (